Genenta Science S.p.A. (SAEN)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Aerospace & Defense
Genenta Science S.p.A.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | 0.7800 | 0.8000 | 0.6600 | 0.7199 | 180,271 |
| Nov 3, 2026 | 0.8359 | 0.9900 | 0.8189 | 0.9850 | 337,503 |
| Nov 2, 2026 | 0.6611 | 0.8700 | 0.6611 | 0.8166 | 1,575,056 |
| Oct 30, 2026 | 0.6200 | 0.6365 | 0.6000 | 0.6183 | 67,198 |
| Oct 29, 2026 | 0.5997 | 0.6200 | 0.5801 | 0.6200 | 153,196 |
| Oct 28, 2026 | 0.5820 | 0.6300 | 0.5820 | 0.6050 | 42,193 |
| Oct 27, 2026 | 0.6330 | 0.6369 | 0.5910 | 0.6182 | 18,900 |
| Oct 26, 2026 | 0.6150 | 0.6340 | 0.5955 | 0.6244 | 28,856 |
| Oct 23, 2026 | 0.6399 | 0.6399 | 0.6300 | 0.6301 | 13,372 |
| Oct 22, 2026 | 0.6610 | 0.6610 | 0.6301 | 0.6301 | 36,968 |
| Oct 21, 2026 | 0.6100 | 0.6598 | 0.6100 | 0.6400 | 36,764 |
| Oct 20, 2026 | 0.6998 | 0.6998 | 0.6100 | 0.6150 | 24,856 |
| Oct 19, 2026 | 0.6500 | 0.6700 | 0.6100 | 0.6588 | 129,387 |
| Oct 16, 2026 | 0.6600 | 0.6787 | 0.6500 | 0.6750 | 39,499 |
| Oct 15, 2026 | 0.7100 | 0.7100 | 0.6606 | 0.6694 | 16,195 |
| Oct 14, 2026 | 0.7050 | 0.7461 | 0.6602 | 0.6602 | 88,477 |
| Oct 13, 2026 | 0.7457 | 0.7515 | 0.7200 | 0.7220 | 34,282 |
| Oct 12, 2026 | 0.7474 | 0.7629 | 0.7400 | 0.7599 | 26,463 |
| Oct 9, 2026 | 0.7270 | 0.7985 | 0.7270 | 0.7852 | 62,965 |
| Oct 8, 2026 | 0.7501 | 0.7771 | 0.7101 | 0.7101 | 53,734 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CMO& Head of Development | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Director | Grant/Award | 20.0K | -- | Mar 30, 2026 | |
| Chief Financial Officer | Grant/Award | 80.0K | -- | Mar 30, 2026 | |
| Chief Executive Officer | Grant/Award | 100.0K | -- | Mar 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Globe 2017 S.r.l. · joint filing· may incl. warrants· filed Oct 2026 | 5.5M | 11.5% | 13D |
Pierluigi Paracchi · may incl. warrants· filed Jan 2026 | 2.3M | 9.8% | 13G |
Eurizon Capital SGR S.p.A. | 360.0K | -- | 13F |
ALLIANZ SE | 234.1K | -- | 13F |
Virtu Financial LLC | 36.9K | -- | 13F |
Mutti Miguel Maria Director | 33.3K | -- | FORM 4 |
Simplicity Wealth,LLC | 20.0K | -- | 13F |
Ground Swell Capital, LLC | 14.4K | -- | 13F |
Financial Planning Navigators CORP | 11.4K | -- | 13F |
GAMMA Investing LLC | 5.4K | -- | 13F |
Insiders
- Galimi FrancescoCMO& Head of Development
- PARACCHI GIACOMOANTONIODirector
- Sharei ArmonDirector
- Mutti Miguel MariaDirector
- SLANSKY RICHARD BChief Financial Officer
- Pierluigi ParacchiChief Executive Officer
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors.
Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
based on 48.22M shares outstanding
30d Avg
137.00K
60d Avg
104.84K
90d Avg
83.91K